John Libbey Eurotext



Sickle cell disease and the risk of malignant haemopathies Ahead of print

1 Association Drepagreffe
2 Centre de référence de la drépanocytose
3 IMRB-Inserm U955, Bât. UITC-EFS, Créteil, France
* Correspondence

The occurrence of haematological malignancies years after allograft rejection or gene therapy for sickle cell disease requires further delineation of the potential role of the disease and its treatments.